Cetuximab biosimilar (Humanwell Healthcare)

西妥昔单抗生物类似药 (人福医药)

Report date: 2022/07/15 15:58:58

Base Information

Drug NameCetuximab biosimilar (Humanwell Healthcare)
Drug Alias Name西妥昔单抗生物仿制药 (Humanwell Healthcare)西妥昔单抗生物类似药 (Humanwell Healthcare)重组人鼠嵌合抗人-EGFR单抗注射液 (Humanwell Healthcare)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHumanwell Healthcare (Group) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Kemei Lide Biomedicine Co LtdHubei Bio-Pharmaceutical Industrial Technological Institute IncHumanwell Healthcare (Group) Co Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A